Stay updated with breaking news from Nasdaq Grna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GreenLight Biosciences Holdings (NASDAQ:GRNA – Get Free Report)’s share price dropped 0% during trading on Thursday . The company traded as low as $0.30 and last traded at $0.30. Approximately 143,100 shares changed hands during trading, a decline of 71% from the average daily volume of 486,986 shares. The stock had previously closed at $0.30. […]
GreenLight Biosciences Holdings (NASDAQ:GRNA – Get Free Report) was the recipient of a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 1,030,000 shares, a decrease of 76.1% from the June 15th total of 4,310,000 shares. Currently, 2.2% of the company’s stock are short sold. […]
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) is one of 275 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare GreenLight Biosciences to similar businesses based on the strength of its profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends. Insider and Institutional Ownership […]
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) is one of 275 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare GreenLight Biosciences to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation. Analyst Recommendations This is […]
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) is one of 263 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare GreenLight Biosciences to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, profitability, valuation and earnings. Institutional and Insider Ownership […]